



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/511,008	02/22/2000	Gregory S. Hageman	20618-000600US	3115

7590

05/20/2003

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111-2422

EXAMINER

LI, QIAN J

ART UNIT

PAPER NUMBER

1632

DATE MAILED: 05/20/2003

20

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/511,008

Applicant(s)

HAGEMAN, GREGORY S.

Examiner

Q. Janice Li

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 March 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-6, 10, 21 and 68-79 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-6, 10, 21 and 68-79 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____
- 4) ☐ Interview Summary (PTO-413) Paper No(s) _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

DETAILED ACTION

Continued Prosecution Application

The request filed on 3/6/03 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/51,008 is acceptable and a CPA has been established. An action on the CPA follows.

Claims 1-6, 10, 21 have been amended. Claims 7-9, 11-20, 22-67 have been canceled. Claims 68-79 are newly submitted. Claims 1-6, 10, 21, and 68-79 are pending. Upon reviewing pending claims, it is determined that further restriction of pending claims is necessary pursuant to 37 CFR 1.142(a).

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S. C. 121:

- I. Claims 1-6, 10, 21, 68-71, 76, and 77 are drawn to a method for assessing a subject's risk for an aortic aneurysm comprising detecting one or more protein markers, wherein the protein to be detected is a drusen-associated marker as defined in claims 70 and 71. Classified in class 435, and subclass 7.1.
- II. Claims 1-6, 68, 69, 72 are drawn to a method for assessing a subject's risk for an aortic aneurysm comprising detecting one or more protein markers, wherein the protein to be detected is associated with cell death as defined in claim 72. Classified in class 435, and subclass 7.1.

Art Unit: 1632

- III. Claims 1-6, 69, 73-75, 79 are drawn to a method for assessing a subject's risk for an aortic aneurysm comprising detecting one or more protein markers, wherein the protein to be detected is drusen-associated dendritic cell markers as defined in claims 73-75 and 79. Classified in class 435, and subclass 7.1.
- IV. Claims 1-6, 69, 78 are drawn to a method for assessing a subject's risk for an aortic aneurysm comprising detecting one or more protein markers, wherein the protein to be detected is a drusen-associated auto-antibody. Classified in class 435, and subclass 7.1.

2. The inventions are distinct, each from the other because of the following reasons.

Inventions II-IV and I are distinct inventions. Inventions are distinct if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case, the different inventions are drawn to detection of numerous protein markers (e.g. recited in claim 1), which are associated with different pathological or physiological events, such as an immunological event, e.g. autoantibody-mediated reaction, disorders in homeostasis of programmed cell death, extracellular matrix, and dendritic cells. The different methods monitoring different criteria, have different standard for measurement, and require distinct technical considerations and search criteria. For example, the search and consideration for autoantibodies are not required in groups I-III, and the search and consideration for various markers associated with the

Art Unit: 1632

homeostasis of the programmed cell death are not required for any of the groups I, III, and IV.

The differences of the Inventions I-IV are further underscored by their divergent classification and independent search criteria.

It is acknowledged that these claims have not been treated as distinct inventions in the original restriction requirement of the parent case. However, during the search and examination process for the parent application, multiple prior art of record were cited for the originally elected species, elastin, now canceled, whereas a search for other proteins claimed are not co-extensive, and numerous protein markers belong to different biological events and require distinct search criteria.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter and different search criteria, examination of all the inventions as listed above would place a severe search and examination burden on the Office, therefore, further restriction for examination purposes as indicated is proper.

3. This application contains claims directed to the following patentably distinct species of the claimed invention: Invention group I is directed to methods detecting different markers associated with drussen-associated proteins, if invention group I is elected, further election of a species drawn to a particular protein is necessary. Invention group II is directed to methods detecting different markers associated with cell death proteins, if invention group II is elected, further election of a species drawn to a

particular marker is necessary. Invention group III is directed to methods detecting different markers of drussen-associated dendritic cells, if invention group III is elected, further election of a species drawn to a particular marker is necessary.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-6, and 69 are generic.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

4. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is advised that where a single claim encompasses more than one invention as defined above, upon election of an invention for examination, said claim will only be examined to the extent that it reads upon the elected invention.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).


6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Q. Janice Li whose telephone number is 703-308-7942. The examiner can normally be reached on 8:30 am - 5 p.m., Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Deborah J. Reynolds can be reached on 703-305-4051. The fax numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-872-9307 for After Final communications.

Art Unit: 1632

Any inquiry of formal matters can be directed to the patent analyst, Dianiece Jacobs, whose telephone number is (703) 305-3388.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235. The faxing of such papers must conform to the notice published in the Official Gazette 1096 OG 30 (November 15, 1989).



Q. Janice Li
Patent Examiner
Art Unit 1632



May 16, 2003